CA3110283A1 - A gaba a receptor ligand - Google Patents
A gaba a receptor ligand Download PDFInfo
- Publication number
- CA3110283A1 CA3110283A1 CA3110283A CA3110283A CA3110283A1 CA 3110283 A1 CA3110283 A1 CA 3110283A1 CA 3110283 A CA3110283 A CA 3110283A CA 3110283 A CA3110283 A CA 3110283A CA 3110283 A1 CA3110283 A1 CA 3110283A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- treatment
- rats
- itch
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18194297.0 | 2018-09-13 | ||
| EP18194297 | 2018-09-13 | ||
| PCT/EP2019/074465 WO2020053377A1 (en) | 2018-09-13 | 2019-09-13 | A gabaa receptor ligand |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3110283A1 true CA3110283A1 (en) | 2020-03-19 |
Family
ID=63579205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3110283A Pending CA3110283A1 (en) | 2018-09-13 | 2019-09-13 | A gaba a receptor ligand |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11396510B2 (https=) |
| EP (1) | EP3849976B1 (https=) |
| JP (1) | JP7353663B2 (https=) |
| KR (1) | KR102712565B1 (https=) |
| CN (1) | CN112714765B (https=) |
| AU (1) | AU2019338236B2 (https=) |
| BR (1) | BR112021004661A2 (https=) |
| CA (1) | CA3110283A1 (https=) |
| DK (1) | DK3849976T3 (https=) |
| EA (1) | EA202190717A1 (https=) |
| ES (1) | ES2935705T3 (https=) |
| FI (1) | FI3849976T3 (https=) |
| HR (1) | HRP20230067T1 (https=) |
| HU (1) | HUE060943T2 (https=) |
| IL (1) | IL281335B2 (https=) |
| LT (1) | LT3849976T (https=) |
| MX (1) | MX2021003010A (https=) |
| PH (1) | PH12021550299A1 (https=) |
| PL (1) | PL3849976T3 (https=) |
| PT (1) | PT3849976T (https=) |
| SG (1) | SG11202101360VA (https=) |
| SI (1) | SI3849976T1 (https=) |
| WO (1) | WO2020053377A1 (https=) |
| ZA (1) | ZA202100976B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4322955A1 (en) | 2021-04-16 | 2024-02-21 | Saniona A/S | A gaba receptor modulator for use in the treatment of pain |
| WO2025056751A1 (en) * | 2023-09-15 | 2025-03-20 | Saniona A/S | A gaba receptor modulator for use in the treatment of absence seizures |
| CN121793969A (zh) * | 2023-09-15 | 2026-04-03 | 萨尼奥纳有限责任公司 | 一种用于治疗与睡眠纺锤波缺陷相关的疾病的gaba受体调节剂 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU675484B2 (en) | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| GB9702524D0 (en) | 1997-02-07 | 1997-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| JP2002535407A (ja) | 1999-01-27 | 2002-10-22 | メルク シャープ エンド ドーム リミテッド | Ｇａｂａ受容体のリガンドとしてのトリアゾロピリダジン誘導体 |
| GB9921150D0 (en) | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
| GB0208394D0 (en) | 2002-04-11 | 2002-05-22 | Merck Sharp & Dohme | Therapeutic agents |
| GB0208392D0 (en) | 2002-04-11 | 2002-05-22 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004087690A2 (en) | 2003-04-03 | 2004-10-14 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex |
| TWI391381B (zh) | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
| TW201029986A (en) | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
| SG11201806393QA (en) | 2016-01-27 | 2018-08-30 | Univ Zuerich | Use of gabaa receptor modulators for treatment of itch |
-
2019
- 2019-09-13 KR KR1020217006185A patent/KR102712565B1/ko active Active
- 2019-09-13 IL IL281335A patent/IL281335B2/en unknown
- 2019-09-13 BR BR112021004661-5A patent/BR112021004661A2/pt unknown
- 2019-09-13 AU AU2019338236A patent/AU2019338236B2/en active Active
- 2019-09-13 SI SI201930443T patent/SI3849976T1/sl unknown
- 2019-09-13 EP EP19765747.1A patent/EP3849976B1/en active Active
- 2019-09-13 JP JP2021514324A patent/JP7353663B2/ja active Active
- 2019-09-13 PT PT197657471T patent/PT3849976T/pt unknown
- 2019-09-13 US US17/272,971 patent/US11396510B2/en active Active
- 2019-09-13 CA CA3110283A patent/CA3110283A1/en active Pending
- 2019-09-13 WO PCT/EP2019/074465 patent/WO2020053377A1/en not_active Ceased
- 2019-09-13 HR HRP20230067TT patent/HRP20230067T1/hr unknown
- 2019-09-13 LT LTEPPCT/EP2019/074465T patent/LT3849976T/lt unknown
- 2019-09-13 CN CN201980059446.2A patent/CN112714765B/zh active Active
- 2019-09-13 SG SG11202101360VA patent/SG11202101360VA/en unknown
- 2019-09-13 HU HUE19765747A patent/HUE060943T2/hu unknown
- 2019-09-13 DK DK19765747.1T patent/DK3849976T3/da active
- 2019-09-13 PL PL19765747.1T patent/PL3849976T3/pl unknown
- 2019-09-13 MX MX2021003010A patent/MX2021003010A/es unknown
- 2019-09-13 EA EA202190717A patent/EA202190717A1/ru unknown
- 2019-09-13 ES ES19765747T patent/ES2935705T3/es active Active
- 2019-09-13 FI FIEP19765747.1T patent/FI3849976T3/fi active
-
2021
- 2021-02-10 PH PH12021550299A patent/PH12021550299A1/en unknown
- 2021-02-12 ZA ZA2021/00976A patent/ZA202100976B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022500445A (ja) | 2022-01-04 |
| AU2019338236A1 (en) | 2021-05-20 |
| EP3849976B1 (en) | 2022-10-26 |
| US11396510B2 (en) | 2022-07-26 |
| JP7353663B2 (ja) | 2023-10-02 |
| DK3849976T3 (da) | 2023-01-23 |
| IL281335B1 (en) | 2024-03-01 |
| IL281335A (en) | 2021-04-29 |
| EA202190717A1 (ru) | 2021-09-22 |
| LT3849976T (lt) | 2023-02-10 |
| CN112714765A (zh) | 2021-04-27 |
| PH12021550299A1 (en) | 2021-10-25 |
| HUE060943T2 (hu) | 2023-04-28 |
| PT3849976T (pt) | 2023-01-13 |
| KR102712565B1 (ko) | 2024-10-02 |
| FI3849976T3 (fi) | 2023-02-19 |
| WO2020053377A1 (en) | 2020-03-19 |
| SG11202101360VA (en) | 2021-03-30 |
| PL3849976T3 (pl) | 2023-02-27 |
| CN112714765B (zh) | 2023-06-30 |
| IL281335B2 (en) | 2024-07-01 |
| US20210332042A1 (en) | 2021-10-28 |
| EP3849976A1 (en) | 2021-07-21 |
| MX2021003010A (es) | 2021-05-27 |
| ES2935705T3 (es) | 2023-03-09 |
| SI3849976T1 (sl) | 2023-03-31 |
| ZA202100976B (en) | 2022-08-31 |
| HRP20230067T1 (hr) | 2023-03-17 |
| KR20210061338A (ko) | 2021-05-27 |
| AU2019338236B2 (en) | 2025-01-09 |
| BR112021004661A2 (pt) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Machelska et al. | Peripheral effects of the κ-opioid agonist EMD 61753 on pain and inflammation in rats and humans | |
| CN107922420B (zh) | 用于治疗社交障碍和药物使用障碍的治疗性化合物和组合物 | |
| EP3444249B1 (en) | Sodium channel blockers, preparation method thereof and use thereof | |
| EA021303B1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
| AU2019338236B2 (en) | A GABAA receptor ligand | |
| DE3811274A1 (de) | Neue anwendungen von dopamin rezeptor-agonisten | |
| WO2001008705A1 (en) | Remedies for neurogenic pains | |
| KR102015484B1 (ko) | 순수한 5-ht6 수용체 길항제와 아세틸콜린에스테라제 저해제의 조합물 | |
| JP2020525480A (ja) | 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用 | |
| EP1183025B1 (en) | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | |
| JP2020525446A (ja) | 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 | |
| HK40057209A (en) | A gabaa receptor ligand | |
| HK40057209B (en) | A gabaa receptor ligand | |
| KR20240012533A (ko) | 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도 | |
| EP2588109A1 (en) | Use of kynurenic acid amide derivatives for the treatment of huntington's disease | |
| CN117159514A (zh) | 桤木酮在制备预防或治疗特应性皮炎药物中的应用 | |
| AU2015363757B2 (en) | Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists | |
| EA042675B1 (ru) | Лиганд рецептора гамк-а | |
| WO2025042610A1 (en) | Pifithrin analogues and methods of treating rett syndrome | |
| JP2023046235A (ja) | 医薬組成物及びｓｔａｔ３のリン酸化阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240821 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240821 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240905 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240905 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241220 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241223 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241223 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250425 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250905 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250905 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250929 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260128 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260128 |